Form 4: Neogenomics Executive Warren Stone Reports Stock Transactions
SEC Form 4
Warren Stone, Chief Commercial Officer of Neogenomics, reports the vesting and disposal of restricted stock units to cover tax obligations, along with the acquisition of additional stock options and units.
Summary
- Warren Stone, Chief Commercial Officer of Neogenomics, filed a Form 4 detailing changes in beneficial ownership.
- On May 11, 2024, Stone vested 9,612 restricted stock units, which converted into common stock.
- He disposed of 2,341 shares of common stock at $14.86 to satisfy tax withholding obligations related to the vesting of the restricted stock units.
- Stone also acquired 9,612 restricted stock units on the same day.
- Following these transactions, Stone directly owns 100,658 shares of Neogenomics common stock.
- The filing also details Stone's holdings of various stock options and performance stock units with different vesting schedules and performance criteria.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral. It reflects standard compensation practices and insider trading reporting.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are common compensation practices in the biotechnology and diagnostics industries.
- Vesting schedules and performance-based criteria are typical mechanisms used to align executive compensation with company performance.
- Companies like Exact Sciences, Guardant Health, and Invitae also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine compensation-related activities.
- Employees may be impacted through the vesting of their own stock options and restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 12/01/2022 | Mr. Stone was granted 166,113 stock options. |
| 05/11/2023 | Mr. Stone was granted 28,838 restricted stock units, 53,969 stock options, and 21,204 performance stock units. |
| 02/23/2024 | Mr. Stone was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units. |
| 05/02/2024 | Mr. Stone was granted 29,976 stock options, 17,905 restricted stock units, and 17,908 performance stock units. |
| 05/11/2024 | Date of the reported transactions: vesting of restricted stock units, disposal of shares for tax obligations, and acquisition of restricted stock units. |
| 05/14/2024 | Date of the Form 4 filing. |
| 05/11/2026 | Expiration date for performance stock units granted on May 11, 2023. |
| 02/23/2027 | Expiration date for performance stock units granted on February 23, 2024. |
| 05/02/2027 | Expiration date for performance stock units granted on May 2, 2024. |
| 12/01/2029 | Expiration date for stock options granted on December 1, 2022. |
| 05/11/2030 | Expiration date for stock options granted on May 11, 2023. |
| 02/23/2034 | Expiration date for stock options granted on February 23, 2024. |
| 05/02/2034 | Expiration date for stock options granted on May 2, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.